PDGF-BB was approved for treatment of diabetic foot ulcers by the FDA [44], and it was reported that there is a more pronounced effect on myocardial angiogenesis when combined with PDGF-BB and b-FGF [45]. The gene discussed is FGF2; the disease is diabetic foot.